https://openbell.ai/ 2026-11-04T10:30:44.971Z hourly 1.0 https://openbell.ai/support 2026-11-04T10:30:44.971Z monthly 0.7 https://openbell.ai/privacy 2026-11-04T10:30:44.971Z monthly 0.5 https://openbell.ai/terms 2026-11-04T10:30:44.971Z monthly 0.5 https://openbell.ai/feed.json 2026-11-04T10:30:44.971Z hourly 0.8 https://openbell.ai/news/BGEO:1793786541000 2026-11-04T10:02:21.000Z daily 0.9 https://cdn.brandfetch.io/BGEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lion Finance Group Reports Higher Q3 Attributable Profit and Net Operating Income Lion Finance Group reported third-quarter attributable profit of 661.9 million Georgian Lari, up from 547.2 million GEL a year earlier. Net operating income also increased, though the company did not provide a figure for the growth. The results cover the three months ending in 2026. https://openbell.ai/news/NVO:1793786516000 2026-11-04T10:01:56.000Z daily 0.9 https://cdn.brandfetch.io/NVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Novo Nordisk Reports Q3 2026 Results and Raises Full-Year Guidance Novo Nordisk reported third-quarter 2026 sales of 79.19 billion Danish kroner, up 6% year over year, with the recently launched Wegovy pill contributing 5.39 billion kroner. Citing strong uptake of its GLP-1 products, the company raised its full-year 2026 guidance for sales and adjusted operating profit growth to -2% to 2% at constant exchange rates, an improvement of about three percentage points from its previous outlook. https://openbell.ai/news/CHT:1793786507000 2026-11-04T10:01:47.000Z daily 0.9 https://cdn.brandfetch.io/CHT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Third Quarter of 2026 Chunghwa Telecom reported unaudited third-quarter 2026 revenue of NT$67.59 billion, up 16.7% year over year and above the high end of its guidance. Revenue, profit and earnings per share reached their highest third-quarter levels since 2009, supported by 6.3% growth in the Consumer Business Group, 8.2% growth in the Enterprise Business Group on strong ICT performance, and a one-off gain from asset revitalization. Management said it remains confident of meeting its full-year guidance. https://openbell.ai/news/MKS:1793784730000 2026-11-04T09:32:10.000Z daily 0.9 https://cdn.brandfetch.io/MKS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Marks & Spencer Announces Interim Results for 26 Weeks Ended 26 September 2026 Marks & Spencer reported interim results for the 26 weeks ended 26 September 2026, with food sales up 13.9% year over year and UK market-share gains. Sales in Fashion, Home & Beauty rose 17.5%. The company also reported a rebound in profit performance, but the article provided no specific profit figures or stock-market reaction. https://openbell.ai/news/GL9:1793784724000 2026-11-04T09:32:04.000Z daily 0.9 https://cdn.brandfetch.io/GL9/w/400/h/400?c=1idopYfmtR7ZKg8QMud Glanbia Raises FY2026 Adjusted EPS Growth Guidance Glanbia reported a 9.9% increase in like-for-like revenue for the nine months ended October 3, 2026, driven by 4.2% volume growth and a 5.7% rise in pricing. Based on the performance, it raised its full-year 2026 adjusted EPS growth guidance to 22%–24%. https://openbell.ai/news/700:1793784707000 2026-11-04T09:31:47.000Z daily 0.9 https://cdn.brandfetch.io/700/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oracle Cancels $7 Billion AI Chip-Leasing Deal with Tencent Oracle canceled a reported five-year, $7 billion deal to provide Tencent access to about 100,000 advanced AI chips in Southeast Asian data centers. The cancellation reportedly followed U.S. administration pressure over supplying advanced AI technology to Chinese companies, limiting Tencent’s access to the hardware for overseas operations and underscoring regulatory tensions for U.S. cloud providers serving Chinese AI firms. https://openbell.ai/news/A5G:1793784691000 2026-11-04T09:31:31.000Z daily 0.9 https://cdn.brandfetch.io/A5G/w/400/h/400?c=1idopYfmtR7ZKg8QMud AIB Group Reports Nine-Month Financial Results and Upgrades FY26 Guidance AIB Group reported nine-month net interest income of €2.87 billion, up 2% year over year, while total income increased 3%; third-quarter net interest income was €1.0 billion. The bank raised its FY2026 net interest income guidance to above €3.85 billion from above €3.8 billion, citing performance supported primarily by higher average volumes. AIB said its search for a new CFO is well advanced and plans to outline its strategy through 2030 alongside its 2026 annual results in March 2027. https://openbell.ai/news/TUNE:1793782917000 2026-11-04T09:01:57.000Z daily 0.9 https://cdn.brandfetch.io/TUNE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Focusrite plc Announces Interim Results for the Six Months Ended 31 August 2026 Focusrite reported revenue of £90.3 million for the six months ended 31 August 2026, up 2.7% as reported and 2.5% organically, with a gross margin of 46.6%. Adjusted EBITDA rose 10.9% to £15.8 million, adjusted operating profit increased 14.7% to £11.1 million, and adjusted diluted EPS grew 25.5% to 12.8p, partly helped by a £2.4 million US tariff refund. Net debt improved by £9.3 million to a net cash position of £1.5 million, and the company raised its interim dividend 3% to 2.16p. Focusrite cited product-development and operational-efficiency investments and scheduled a Capital Markets Event for 25 November 2026. https://openbell.ai/news/MTRO:1793782916000 2026-11-04T09:01:56.000Z daily 0.9 https://cdn.brandfetch.io/MTRO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Metro Bank Holdings PLC Reports Third Quarter 2026 Trading Update Metro Bank reported 37% year-on-year growth in target lending segments in Q3 2026, including corporate, commercial, SME and specialist mortgage lending. Structural net interest margin expanded by 42 basis points to 3.45%, reaching the bank’s full-year guidance range. Customer deposits totaled £13.0 billion, with a net loan-to-deposit ratio of 71%. Management reaffirmed its existing guidance for the rest of the year, citing underlying momentum and operating leverage. https://openbell.ai/news/MPAL:1793782912000 2026-11-04T09:01:52.000Z daily 0.9 https://cdn.brandfetch.io/MPAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud MedPal AI plc Announces October 2026 Trading Update MedPal AI reported unaudited October 2026 group revenue of approximately £4.1 million, up from £3.2 million in September. Its New Health division generated £3.63 million, a 33% month-on-month increase, with more than 29,400 orders. Repeat-order revenue more than doubled to £1.34 million, or 37% of the division’s revenue, and has grown more than thirteen-fold since August. Group recurring revenue was approximately £1.8 million, equal to 45% of total revenue, supporting a pro forma annualised run-rate of £49 million. https://openbell.ai/news/ORC.A:1793782911000 2026-11-04T09:01:51.000Z daily 0.9 https://cdn.brandfetch.io/ORC.A/w/400/h/400?c=1idopYfmtR7ZKg8QMud Orca Energy Group Inc. Announces Special Meeting to Consider Liquidation and Delisting Orca Energy Group Inc. mailed shareholders a management information circular for a special meeting on November 24, 2026. Shareholders will vote on a non-binding proposal authorizing the board to plan a voluntary liquidation and on a proposal to delist the company’s shares from the TSX Venture Exchange. The board will determine the timing, with delisting expected before June 30, 2027. https://openbell.ai/news/GSM:1793782886000 2026-11-04T09:01:26.000Z daily 0.9 https://cdn.brandfetch.io/GSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ferroglobe Reports Third Quarter 2026 Financial Results and Announces Profitability Improvement Plan Ferroglobe reported Q3 2026 sales of $369.8 million, down 2.3% sequentially but up 18.6% year over year, and adjusted EBITDA of negative $2.4 million. The company attributed the loss primarily to higher energy costs linked to the Middle East conflict and excess ferrosilicon imports into Europe. Its profitability plan includes closing five plants and cutting overhead costs by 20%, targeting $85 million to $115 million in adjusted EBITDA improvement at full run rate. Chief Legal Officer and Group Company Secretary Thomas Wiesner will step down effective November 4, 2026. https://openbell.ai/news/BARN:1793781151000 2026-11-04T08:32:31.000Z daily 0.9 https://cdn.brandfetch.io/BARN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barry Callebaut Revises Profit Forecast Downward Amid Rising Cocoa Prices Barry Callebaut lowered its profit forecast, citing an expected rise in cocoa prices. The company said the revision reflects changing conditions in the cocoa market; the article provides no specific financial figures or stock-price impact. https://openbell.ai/news/TX:1793781136000 2026-11-04T08:32:16.000Z daily 0.9 https://cdn.brandfetch.io/TX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ternium Returns to Profitability in Third Quarter Ternium S.A. reported a return to profitability in the third quarter, improving its financial performance from previous periods. The Latin American steel producer attributed the results to its operations and market conditions, but the report provided no specific revenue, profit, or growth figures. https://openbell.ai/news/BAYN:1793781120000 2026-11-04T08:32:00.000Z daily 0.9 https://cdn.brandfetch.io/BAYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bayer Receives First-Line Approval for Sevabertinib in China China’s National Medical Products Administration approved Bayer’s Sevabertinib as a first-line treatment for advanced HER2-mutated non-small cell lung cancer. The drug was previously approved in China only for patients who had received prior systemic therapy. The approval expands its use in China, following first-line approvals in Japan and the United States earlier this year. https://openbell.ai/news/HEI:1793781112000 2026-11-04T08:31:52.000Z daily 0.9 https://cdn.brandfetch.io/HEI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Heidelberg Materials Reports Strong Q3 2026 Results and Expands Cost-Saving Initiative Heidelberg Materials reported third-quarter 2026 revenue of €6.41 billion, up 10% year over year, and result from current operations (RCO) of €1.28 billion, up 9%. The company cited strong business in Europe and continued growth in North America, and reaffirmed its full-year RCO outlook of €3.40 billion to €3.65 billion. It expanded its Transformation Accelerator program, targeting an additional €300 million in savings by the end of 2028 through operational efficiencies and structural changes, particularly in Europe. https://openbell.ai/news/VPK:1793781107000 2026-11-04T08:31:47.000Z daily 0.9 https://cdn.brandfetch.io/VPK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vopak Reports Strong YTD Performance and Raises FY 2026 Outlook Vopak reported strong year-to-date performance in 2026 and raised its full-year outlook. Third-quarter net profit was EUR 142 million, including exceptional items. The company cited robust operational results across its global storage and handling activities; no revenue, growth percentage, or stock-price impact was reported. https://openbell.ai/news/CCH:1793781101000 2026-11-04T08:31:41.000Z daily 0.9 https://cdn.brandfetch.io/CCH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Coca-Cola HBC Announces Q3 2026 Trading Update and Raises Revenue Guidance Coca-Cola HBC reported third-quarter 2026 organic revenue growth of 9.0%, with organic volumes up 5.4% and revenue per case up 3.4%; reported revenue rose 9.6% to €3.50 billion. The company raised its full-year organic revenue growth guidance to slightly above its previous 6.0%–7.0% range, while maintaining its forecast for organic EBIT growth of 8.0%–10%. Management cited strong execution across its markets and particular strength in Sparkling and Energy. https://openbell.ai/news/WFA:1793779404000 2026-11-04T08:03:24.000Z daily 0.9 https://cdn.brandfetch.io/WFA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Weng Fine Art AG Announces Correction of 2025 Financial Statements Weng Fine Art AG revised its projected 2025 net profit down from EUR 5.9 million to approximately EUR 4.7 million. The correction includes an additional EUR 735,000 inventory write-down amid a weakening art market, a roughly EUR 410,000 write-down of its Artfacts.Net Ltd. investment, and EUR 80,000 in costs for an abandoned acquisition. Expected equity fell from EUR 19 million to approximately EUR 17.8 million. Audited statements are expected before the December 18, 2026 Annual General Meeting. https://openbell.ai/news/BEZ:1793779400000 2026-11-04T08:03:20.000Z daily 0.9 https://cdn.brandfetch.io/BEZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Berentzen-Gruppe Boards Recommend Sazerac Takeover Offer Berentzen-Gruppe AG said on November 3, 2026, that its Executive Board and Supervisory Board recommend shareholders accept Sazerac’s takeover offer. The recommendation follows the start of the offer’s acceptance period and advances the proposed acquisition of the German beverage company by the international spirits producer. The report did not provide financial terms or details of any market reaction. https://openbell.ai/news/ACX:1793779395000 2026-11-04T08:03:15.000Z daily 0.9 https://cdn.brandfetch.io/ACX/w/400/h/400?c=1idopYfmtR7ZKg8QMud bet-at-home.com AG Lowers 2026 Earnings Guidance bet-at-home.com AG lowered its 2026 EBITDA-before-special-items forecast to between EUR -1.6 million and EUR 0.0 million, from EUR 0.0 million to EUR 4.0 million. It also narrowed its gross betting and gaming revenue (GGR) outlook to EUR 46.0 million–EUR 49.0 million, with a current expectation of EUR 47.0 million, versus prior guidance of EUR 46.0 million–EUR 54.0 million. The company attributed the revisions to updated planning assumptions; the article reports no stock-price impact. https://openbell.ai/news/CLBIO:1793779387000 2026-11-04T08:03:07.000Z daily 0.9 https://cdn.brandfetch.io/CLBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Corline Biomedical Issues 2026 Financial Forecast and 2027 Guidance Corline Biomedical AB issued a full-year 2026 financial forecast and market guidance for 2027, based on recently received orders and customer forecasts. The company said the disclosure is intended to clarify its long-term growth potential and was made under the EU Market Abuse Regulation. The article provides no specific financial figures or stock-price impact. https://openbell.ai/news/MZX:1793779386000 2026-11-04T08:03:06.000Z daily 0.9 https://cdn.brandfetch.io/MZX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Masterflex SE Reports Record Earnings for the First Nine Months of 2026 Masterflex SE increased revenue 3.0% to €82.2 million in the first nine months of 2026, from €79.8 million a year earlier. Operating EBIT reached a record €12.3 million, up from €12.1 million, with a 14.9% margin; growth was led by the Life segment, particularly medical technology and food processing. Net debt fell to €1.0 million and the equity ratio rose to 74.1%. Management reaffirmed its full-year 2026 forecast despite geopolitical and macroeconomic challenges. https://openbell.ai/news/PION.B:1793779385000 2026-11-04T08:03:05.000Z daily 0.9 https://cdn.brandfetch.io/PION.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud PION Group Reports Significant Increase in Q3 2026 Operating Profit PION Group reported a significant increase in operating profit in the third quarter of 2026, citing progress in its staffing and recruitment businesses. The article provides no specific profit or revenue figures, growth percentages, or stock-market impact. https://openbell.ai/news/SQNS:1793779383000 2026-11-04T08:03:03.000Z daily 0.9 https://cdn.brandfetch.io/SQNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sequans Communications Announces Preliminary Unaudited Third Quarter 2026 Financial Results Sequans Communications reported preliminary unaudited third-quarter 2026 revenue of $9.1 million, up 21.9% sequentially and 182.8% year over year. Gross margin rose to 33.0%, compared with 32.9% in the prior quarter and 25.3% a year earlier. Operating loss narrowed to $1.0 million from $7.2 million in the second quarter and $24.4 million in the third quarter of 2025. CEO Georges Karam cited continued growth in the core IoT semiconductor business and progress toward profitability. https://openbell.ai/news/LYTIX:1793779374000 2026-11-04T08:02:54.000Z daily 0.9 https://cdn.brandfetch.io/LYTIX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lytix Biopharma's NeoLIPA Treatment Meets Primary Endpoint in Clinical Trial Lytix Biopharma said its combination therapy NeoLIPA met the primary endpoint in a clinical trial for melanoma. The result marks progress for the company’s oncology pipeline of oncolytic molecule therapies targeting solid tumors. The company has not yet provided further trial details or outlined next development steps.